MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines

MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines

Abstract Non-small cell lung cancer (NSCLC) is frequently associated with mutations in receptor tyrosine kinases (RTKs), such as EGFR and ALK. While RTK inhibitors (RTKIs) have proven effective in treating patients with specific RTK mutations, the emergence of resistance to these therapies remains a...

Full description

Saved in:
Bibliographic Details
Main Authors: Hyun-Min Ryu, Deokhoon Kim, Jun Young Choi, Shinkyo Yoon, Ho-Su Lee, Ji Eun Park, Eunjin Lee, Yunkyung Sung, Chang Hoon Lee, Eun-Young Lee, Wanlim Kim, Seyoung Seo, Sang-We Kim, Kang-Seo Park, Dae Ho Lee
Format: Article
Language:English
Published: Springer 2025-08-01
Series:Cellular and Molecular Life Sciences
Subjects:
NSCLC
MED12 mutation
Drug resistance
Receptor tyrosine kinase inhibitor
MEK inhibitor
Online Access:https://doi.org/10.1007/s00018-025-05791-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00018-025-05791-w

Similar Items